热线电话: 021-34661275
产品分类/PRODUCT CLASSIFICATION

上海细胞库

人源细胞系| 稳转细胞系| 基因敲除株| 基因点突变细胞株| 基因过表达细胞株| 重组细胞系| 猪的细胞系| 马细胞系| 兔的细胞系| 犬的细胞系| 山羊的细胞系| 鱼的细胞系| 猴的细胞系| 仓鼠的细胞系| 狗的细胞系| 牛的细胞| 大鼠细胞系| 小鼠细胞系| 其他细胞系|

原代细胞

原代细胞| 永生化细胞|

细胞培养

血清| 无血清冻存| 细胞培养试剂盒| 普通培养基| 完全培养基| 细胞污染预防| 细胞污染清除| 细胞培养辅助试剂|

细胞服务

STR鉴定服务| ATCC代购服务|

酶联试剂盒

人ELISA试剂盒| 大鼠ELISA试剂盒| 小鼠ELISA试剂盒| 兔ELISA试剂盒| 猪ELISA试剂盒| 鱼ELISA试剂盒| 牛ELISA试剂盒| 犬ELISA试剂盒| 鸭ELISA试剂盒| 豚鼠ELISA试剂盒| 鸡ELISA试剂盒| 绵羊ELISA试剂盒| 山羊ELISA试剂盒| 仓鼠ELISA试剂盒| 植物ELISA试剂盒| 药残留类试剂盒| 其他ELISA试剂盒|

生化试剂盒

生化试剂盒| 微量法检测盒| 分光法检测盒| 胶体金检测盒|

PCR试剂盒

荧光探针PCR试剂盒| 染料荧光PCR试剂盒| 核酸扩增/纯化| 普通PCR检测试剂盒| 质粒菌种感受态|

抗体蛋白

蛋白多肽| 抗体| 免疫组化| 免疫球蛋白|

试剂耗材

标准试液| 科研试剂| 缓 冲 液| 实验耗材| 高效液相色谱对照品|

首页 > 抗体蛋白 > 抗体
PE/Cyanine7 anti-mouse I-A/I-E Antibody
产品名称：
PE/Cyanine7 anti-mouse I-A/I-E Antibody
产品类别：
抗体
产品编号：
107629
产品应用：
107629
[价格]
规格 价格 库存
25?g ￥ 1480 1

产品详情

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Activated C57BL/6 mouse spleen cells
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with PE/Cyanine7 under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.06 ?g per million cells in 100 ?l volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

The M5/114.15.2 antibody reacts with a polymorphic determinant shared by the I-Ab, I-Ad, I-Aq, I-Ed, and I-Ek MHC class II alloantigens from mice carrying H-2p,r,q,b,d,u haplotypes. Clone M5/114.15.2 however does not react wtih I-Af, I-Ak, or I-As MHC class II alloantigens.1

Additional reported applications (for the relevant formats) include: immunoprecipitation1, immunohistochemistry of frozen sections2,3,6, in vitro and in vivo blocking of antigen presentation or ligand binding4-7, and spatial biology (IBEX)17,18. The Ultra-LEAF? purified antibody (Endotoxin < 0.01 EU/?g, Azide-Free, 0.2 ?m filtered) is recommended for functional assays (Cat. Nos. 107655 & 107656).

Additional Product Notes
BioLegend is in the process of converting the name PE/Cy7 to PE/Cyanine7. The dye molecule remains the same, so you should expect the same quality and performance from our PE/Cyanine7 products. Please contact Technical Service if you have any questions.
Application References

(PubMed link indicates BioLegend citation)
  1. Bhattacharya A, et al. 1981. J. Immunol. 127:2488. (IP)
  2. Viville S, et al. 1993. Cell 72:635. (IHC)
  3. Nelson AJ, et al. 1993. J. Immunol. 151:2453. (IHC)
  4. Shi Y, et al. 1998. J. Exp. Med. 187:367. (Block)
  5. Yamashita I, et al. 1993. Int. Immunol. 5:1139.
  6. Guo M, et al. 1995. Zygote 3:65. (IHC)
  7. Kim A, et al. 2004. Exp. Mol. Med. 36:428. (Block)
  8. Luckashenak NA, et al. 2006. J. Immunol. 177:5177.
  9. Venanzi ES, et al. 2007. J. Immunol. 179:5693.
  10. Christensen SR, et al. 2006. Immunity 25:417. PubMed
  11. Matte-Martone C, et al. 2008. Blood 111:3884. PubMed
  12. De Pascalis R, et al. 2008. Infect. Immun. 76:4311. PubMed
  13. Kuns RD, et al. 2009. Blood 113:5999. PubMed
  14. Sabatino JJ, et al. 2011. J. Exp. Med. 208:81. PubMed
  15. Draber P, et al. 2011. Mol Cell Biol. 22:4550. PubMed
  16. Fu H, et al. 2014. Nat Commun. 5:3436. PubMed
  17. Radtke?AJ,?et al.?2020.?Proc Natl Acad Sci U S A.?117:33455-65. (SB)?PubMed
  18. Radtke?AJ,?et al.?2022.?Nat Protoc.?17:378-401. (SB)?PubMed
Product Citations
  1. Shi M, et al. 2021. Theranostics. 11:2349. PubMed
  2. Hutton C, et al. 2021. Cancer Cell. 39:1227. PubMed
  3. Zhao J, et al. 2021. Emerg Microbes Infect. 10:913. PubMed
  4. Li Y et al. 2017. EBioMedicine. 18:188-198 . PubMed
  5. Rezende R, et al. 2015. Nat Commun. 6: 8726. PubMed
  6. Pandey S, et al. 2020. Cell Syst. 11:495. PubMed
  7. Rosa FF, et al. 2020. Bio Protoc. 10:e3619. PubMed
  8. Kim TJ, et al. 2019. Nat Commun. 10:3258. PubMed
  9. Pingili AK, et al. 2021. Cell Reports. 35(12):109285. PubMed
  10. Nguyen SL, et al. 2021. Sci Rep. 11:4217. PubMed
  11. Bartleson JM, et al. 2020. Nat Immunol. 1384:21. PubMed
  12. Grohmann M et al. 2018. Cell. 175(5):1289-1306 . PubMed
  13. Zhang J, et al. 2021. J Leukoc Biol. 110:485. PubMed
  14. Rolfes S, et al. 2020. Neurobiol Dis. 144:105024. PubMed
  15. Wang Z, et al. 2021. J Virol. 95:e0141421. PubMed
  16. Sheng K, et al. 2014. PLoS One. 9:95208. PubMed
  17. Wei SC, et al. 2020. Cancer Discov. . PubMed
  18. He W et al. 2018. Immunity. 49(6):1175-1190 . PubMed
  19. Li J, et al. 2020. Cancer Immunol Res. 0.529166667. PubMed
  20. Domeier P, et al. 2016. J Exp Med. 213: 715 - 732. PubMed
  21. Soni C, et al. 2014. J Immunol. 193:4400. PubMed
  22. Lagares D, et al. 2017. Sci Transl Med. 9:eaal3765. PubMed
  23. Derecka M, et al. 2020. Nat Immunol. 261:21. PubMed
  24. Li J, et al. 2018. Immunity. 49:178. PubMed
  25. , et al. 2021. Eur J Immunol. 51:2708. PubMed
  26. Yang J, et al. 2020. Nature. 586:572. PubMed
  27. Ahadome S, et al. 2016. JCI Insight. 1:e87012. PubMed
  28. Jager SE, et al. 2020. Glia. 68(7):1375-1395. PubMed
  29. Horiguchi H, et al. 2019. Genes Dev. 33:1641. PubMed
  30. Tan X, et al. 2021. Sci Adv. 7: . PubMed
  31. Zeng W, et al. 2021. STAR Protocols. 2(1):100361. PubMed
  32. Toomey CB, et al. 2018. Invest Ophthalmol Vis Sci. 59:662. PubMed
  33. Seki T, et al. 2015. J Biochem. 158: 485 - 495. PubMed
  34. Sydney Lavoie et al. 2019. eLife. 8 pii: e39982. PubMed
  35. Ma W, et al. 2017. Cell Death & Disease. 10.1038/cddis.2017.47. PubMed
  36. Hu Y, et al. 2021. Cell Death Dis. 12:743. PubMed
  37. Mossadegh–Keller N, et al. 2019. Bio Protoc. 9:5. PubMed
  38. Lebel M?, et al. 2020. Nat Commun. 3.051388889. PubMed
  39. Sakamoto K, et al. 2021. Immunity. 54:2321. PubMed
  40. He C, et al. 2022. Nat Commun. 13:5459. PubMed
  41. Williams JB, et al. 2020. Nat Commun. 0.876388889. PubMed
  42. Rosenbaum SR, et al. 2020. Cell Rep. 30:510. PubMed
  43. Kriegsman BA, et al. 2019. J Immunol. 203:1999. PubMed
  44. Zhang C, et al. 2021. J Immunother Cancer. 9:. PubMed
  45. Chakraborty M, et al. 2021. Cell Reports. 34(2):108609. PubMed
  46. Wei Y, et al. 2021. Endocrinology. 162(8):. PubMed
  47. Natale CA, et al. 2018. Elife. 7. PubMed
  48. Wong E, et al. 2015. J Immunol. 194:4130. PubMed
  49. Yin X, et al. 2020. Cell Rep. 33:108278. PubMed
  50. Chen B, et al. 2021. Cell. 184:6262. PubMed
  51. Guan D, et al. 2021. Cell Death Dis. 12:431. PubMed
  52. Sakamoto K, et al. 2022. STAR Protoc. 3:101052. PubMed
  53. Maller O, et al. 2020. Nat Mater. 20:548. PubMed
  54. Henkle TR, et al. 2021. Cancer Res. 81:4560. PubMed
  55. Rappe JCF, et al. 2021. J Exp Med. 218:. PubMed
  56. Dourcy M, et al. 2020. Mucosal Immunol. 13:799. PubMed
  57. Zhang M, et al. 2022. iScience. 25:104490. PubMed
  58. Li CY, et al. 2022. Int J Mol Sci. 23:. PubMed
  59. Kubli SP, et al. 2019. Nat Commun. 10:2678. PubMed
RRID
AB_2290801 (BioLegend Cat. No. 107629) AB_2069376 (BioLegend Cat. No. 107630)

Antigen Details

Structure
MHC class II
Distribution

B cell and activated T cells, APCs of the H-2b,d,q,r bearing mice

Function
Antigen presentation
Ligand/Receptor
CD3/TCR, CD4
Cell Type
Antigen-presenting cells, B cells, Dendritic cells, T cells, Tregs
Biology Area
Immunology, Innate Immunity
Molecular Family
MHC Antigens
Antigen References

1. Watts C. 1997. Ann. Rev. Immunol. 15:821.
2. Pamer E, et al. 1998. Ann. Rev. Immunol. 16:323.

Gene ID
14961 View all products for this Gene ID 14969 View all products for this Gene ID
UniProt
View information about I-A/I-E on UniProt.org

联系我们

TEL：021-34661275 　点击拨打热线